Lexicon Pharmaceuticals
LXRX
149 hedge funds and large institutions have $875M invested in Lexicon Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 36 increasing their positions, 36 reducing their positions, and 30 closing their positions.
3,001% more call options, than puts
Call options by funds: $5.15M | Put options by funds: $166K
73% more capital invested
Capital invested by funds: $505M → $875M (+$370M)
50% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 30
10% more funds holding
Funds holding: 136 → 149 (+13)
5.75% more ownership
Funds ownership: 76.33% → 82.08% (+5.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$39.8M |
| 2 |
BlackRock
New York
|
+$27.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.7M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.42M |
| 2 |
Jane Street
New York
|
-$5.19M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.71M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.5M |
| 5 |
CBU
CIBC Bancorp USA
Chicago,
Illinois
|
-$3.48M |
LXRX Hedge Fund Activity: Q2 2026 in Review
149 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2026, worth a combined $875M — up 73% from $505M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new LXRX positions and 30 closed out — a net gain of 15 holders — while 36 added to existing stakes and 36 trimmed.
The largest buyer was Artal Group, adding an estimated $39.8M. The largest seller was Millennium Management, cutting an estimated $7.42M.
- 149 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2026, up from 136 in Q1 2026.
- Funds reported $875M of Lexicon Pharmaceuticals stock for Q2 2026, up 73% quarter-over-quarter.
- 45 funds opened new Lexicon Pharmaceuticals positions in Q2 2026 and 30 closed out, a net change of +15 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2026 was Artal Group, an estimated $39.8M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2026 was Millennium Management, an estimated $7.42M sold.
Based on aggregated 13F filings for Q2 2026.